Spiderwort secures $13.2M USD in Series A Financing to Accelerate Clinical Trials of Revolutionary Biomaterials
Spiderwort to use funding to advance biotechnology innovations to treat acute spinal cord injuries. OTTAWA – July 12, 2022 – Spiderwort Inc., the biotech company innovating in cellulose-based tissue scaffolding to treat acute spinal cord injuries, today announced the successful […]
FDA grants a Breakthrough Device Designation for Spiderwort Spinal Cord Technology
Spiderwort Inc., a Canadian medical device company developing innovative biomaterials for regenerative medicine, is pleased to announce that the U.S. Food and Drug Administration (FDA) has designated CelluBridgeTM, Spiderwort’s Spinal Cord Scaffold Implant, as a “Breakthrough Device”. The FDA Breakthrough […]
Spiderwort closes $2.5M USD Series Seed financing to continue work on transformative biomaterials
Spiderwort Inc., an innovator in biomaterials, is pleased to announce the closing of their $2.5 million USD Series Seed round financing. The financing was led by Horizons Ventures, and supported by a number of groups, most notably investors from the […]
Spiderwort gaining momentum with the closing of Friends and Family round; naming of key advisors
OTTAWA – June 10, 2019 – Momentum is building as Spiderwort—an innovator in biomaterials that has the potential to transform healthcare—has crossed two major milestones with the closing of its Friends and Family funding round, and the naming of its […]
Please contact us for press kit or media inquiries.
Contact Us